ArticleBMJ open2025

Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE.

Nick Daneman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.